AMP German Cannabis Group Hires Experienced Sales Director from Canopy Growth

ERFURT and BERLIN, Germany – September 15th, 2020 – AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028), a licenced importer of medical cannabis into Germany, is pleased to announce the appointment of Mr. Marc Wälken as Sales Director, effective immediately. 

Mr. Wälken joins AMP from Spectrum Therapeutics, a brand of Canopy Growth Germany GmbH, a wholly-owned subsidiary of Canopy Growth Corporation (TSX: WEED), one of the largest importers of medical cannabis into Germany, where he was Areas Sales Manager and Key Account Manager. Prior to that, Mr. Wälken was a sales representative for Roche Pharma AG, the German division of The Roche Group, a global pharmaceutical company based in Switzerland. 

Mr. Wälken is responsible for implementing and managing sales strategies to introduce AMP’s branded cannabis products and build AMP’s national sales team. The development of a national sales team is important in generating strong revenue growth. It will initially focus on selling imported medical cannabis to mid-sized pharmaceutical distributors and large pharmacies who do not have supply access to imported medical cannabis outside Europe. 

AMP’s goal is to be one of the leading German medical cannabis suppliers by 2021 by building a reliable supply source of imported medical cannabis and developing a national sales team to sell to pharmaceutical distributors and pharmacists, thereby ensuring reliable prescription fulfillment across Germany of AMP medical cannabis products. 

In July 2020, AMP started importing and selling to national pharmaceutical distributor branded medical cannabis flower from the Netherlands and will begin importing flowers and extracts under the AMP medical cannabis brand beginning in Q4 2020, from Canada and Europe. 

Dr. Stefan Feuerstein, Director and President of AMP, commented: “Mr. Wälken is one of the leading experts in the industry. His broad experience in the pharmaceutical and medical cannabis industry will be critical in building AMP’s national sales team covering all sixteen German states.” 

Mr. Marc Wälken, Sales Director of AMP, commented: “I believe that AMP’s strategy of focusing on supplying mid-sized pharmaceutical distributors and big pharmacies will be successful, especially as AMP will invest in information events for pharmacists and doctors, thus enlarging their knowledge about the medical use of its medical cannabis products.” 

About AMP German Cannabis Group 

AMP German Cannabis Group is licensed to import European Union – Good Manufacturing Practice (EU-GMP) medical cannabis from Europe and elsewhere into Germany. AMP sources, stores, transports, delivers, 

and sells medical cannabis products to pharmaceutical distributors or pharmacists directly, the only point-of-sale for medical cannabis to German patients with a physician’s prescription. 

AMP has entered into a non-exclusive distribution agreement for medical cannabis with a leading distributor of pharmaceuticals products to more than 13,000 pharmacies throughout Germany. AMP imports medical cannabis from the Netherlands and Canada. 

For more information, please visit: 


Mr. Alex Blodgett, CEO and Director 

Telephone: +1 236-833-1602 


AMP social media links: 

• Twitter: 

• LinkedIn: 

• Facebook: 

• Instagram: 

Media Kit: 

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. 

This news release contains forward-looking statements that are based on the Company’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans and milestones and the timing thereof. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. 

SOURCE AMP German Cannabis Group Inc.